Pfizer Inc. said on Monday it has filed a second lawsuit against Metsera and its controlling shareholders, as well as Novo Nordisk in a Delaware federal court, accusing them of anticompetitive conduct.
The latest lawsuit follows Danish drugmaker Novo’s bold and unsolicited counter-bid for U.S.-based Metsera, surprising Pfizer which had already locked in a deal with Metsera valued at about $7.3 billion.
Pfizer, which does not currently sell a weight-loss drug, is betting on Metsera to help it enter the $150 billion obesity market and offset falling COVID-related revenue and looming patent expirations.
Metsera is